Phase II evaluation of dacarbazine (D), mitomycin-C (M), doxorubicin (A) and cisplatin (P) (DMAP) plus sargramostim (GM-CSF) in the treatment of advanced, persistent, or recurrent leiomyosarcoma of the uterus: A Gynecologic Oncology Group (GOG) study

Autor:	Harry J. Long, J. A. Blessing, J. Sorosky
Rok vydání:	2005
Předmět:	Oncology Cisplatin Cancer Research medicine.medical_specialty business.industry Dacarbazine Mitomycin C Uterus Gynecologic oncology Recurrent Leiomyosarcoma body regions medicine.anatomical_structure Sargramostim Internal medicine medicine Doxorubicin business medicine.drug
Zdroj:	Journal of Clinical Oncology. 23:5077-5077
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2005.23.16_suppl.5077
Popis:	5077 Background: Following a reported 23% objective response rate for MAP (Edmonson, et al: Gynecol Oncol 2002; 85:507–510) in patients with advanced uterine leiomyosarcoma, and preliminary data su...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6afe523cff4009685fb2f83c70ef5f58 https://doi.org/10.1200/jco.2005.23.16_suppl.5077 Zobrazit plný text záznamu